The traditional pharmaceutical development funnel is currently facing a massive overhaul as
The silent breach of North American research facilities by the threat group UNC6508 represents a
The rapid evolution of high-fidelity cardiac monitoring and specialized machine learning in 2026 has transformed the standard electrocardiogram into an unexpectedly sensitive source of biometric information. While physicians have traditionally utilized these electrical recordings to identify
The recent failure of the high-profile Phase 3 LAGOON trial involving Zepzelca has sent shockwaves through the oncology community, raising urgent questions about the reliability of surrogate endpoints in modern drug regulation. While the drug initially received accelerated approval based on a
The convergence of advanced medical telemetry and distributed cloud architectures has transformed
Ivan Kairatov is a seasoned Biopharma expert with a distinguished career at the intersection of
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
In 2026, boards and customers are asking a direct question: can promising science be turned into
The pharmaceutical sector is entering a decisive phase as obesity therapeutics gain more ground as
Advanced Therapy Medicinal Products cannot be scaled the same way biologics were. The core
The End of the Old Biopharma Playbook The biopharmaceutical industry is confronting a structural
The biological complexity of cancer requires a precision that traditional treatments often lack, creating a desperate need for solutions that can adapt to the unique genetic profile of every individual patient. While generic chemotherapy and radiation have long been the standard of care, the
Developing therapeutic interventions for the central nervous system has long been regarded as one
Ivan Kairatov is a seasoned Biopharma expert whose career has been defined by the pursuit of
